Literature DB >> 8735629

Receptors for kinins in the human isolated umbilical vein.

F Gobeil1, L H Pheng, I Badini, X K Nguyen-Le, A Pizard, A Rizzi, D Blouin, D Regoli.   

Abstract

1. The human umbilical vein has been found to contract in response to bradykinin (BK) and desArg9BK. 2. The rank order of potency of agonists, in the presence of the B1 receptor antagonist Lys[Leu8]desArg9BK, is as follows: [Hyp3, Tyr(Me)8]BK (pD2 8.88) = [Hyp3]BK (pD2 8.86) = LysBK (pD2 8.81) > or = BK (pD2 8.60) >> [Aib7]BK (pD2 6.38) >> desArg9BK and LysdesArg9BK (inactive). 3. Hoe 140 (pA2 8.42) inhibits the effects of BK while other B2 receptor peptide antagonists are very weak and WIN 64338 is practically inactive. 4. Venoconstrictor responses to desArg9BK of fresh tissues increase with time during the in vitro incubation and reach a maximum after 4-6 h. The activity of Hoe 140 (pA2 5.48) is negligible against B1 receptor agonists. 5. When measured in the presence of the selective B2 receptor antagonist Hoe 140 (400 nM), the order of potency of kinin related peptides on the B1 receptor is Lys[desArg9]BK (pD2 8.60) > desArg9BK (pD2 6.69). BK, LysBK, [Hyp3]BK and other B2 receptor agonists are inactive. 6. The B1 receptor antagonist, Lys[Leu8]desArg9BK (pA2 7.99), inhibits the response of the human vein to B1 receptor agonists (LysdesArg9BK or desArg9BK), but do not alter the effect of BK. 7. The results summarized in this paper indicate that the human isolated umbilical vein is a sensitive preparation containing both B1 and B2 receptors. The human B2 receptor shows some similarity with that of the rabbit (at least for agonist potencies) and differs from the B2 receptor of the guinea-pig. Compared to the rabbit B1 receptor, the human B1 receptor shows low sensitivity to peptides that lack the N-terminal Lys.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735629      PMCID: PMC1909628          DOI: 10.1111/j.1476-5381.1996.tb15401.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

1.  Design of potent non-peptide competitive antagonists of the human bradykinin B2 receptor.

Authors:  J M Salvino; P R Seoane; B D Douty; M M Awad; R E Dolle; W T Houck; D M Faunce; D G Sawutz
Journal:  J Med Chem       Date:  1993-08-20       Impact factor: 7.446

2.  Expression cloning of a rat B2 bradykinin receptor.

Authors:  A E McEachern; E R Shelton; S Bhakta; R Obernolte; C Bach; P Zuppan; J Fujisaki; R W Aldrich; K Jarnagin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

Review 3.  Receptors for bradykinin and related kinins: a critical analysis.

Authors:  D Regoli; D Jukic; F Gobeil; N E Rhaleb
Journal:  Can J Physiol Pharmacol       Date:  1993-08       Impact factor: 2.273

4.  Differential pharmacology of cloned human and mouse B2 bradykinin receptors.

Authors:  J F Hess; J A Borkowski; T Macneil; G Y Stonesifer; J Fraher; C D Strader; R W Ransom
Journal:  Mol Pharmacol       Date:  1994-01       Impact factor: 4.436

5.  Effects of peptide and nonpeptide antagonists of bradykinin B2 receptors on the venoconstrictor action of bradykinin.

Authors:  F Marceau; L Levesque; G Drapeau; F Rioux; J M Salvino; H R Wolfe; P R Seoane; D G Sawutz
Journal:  J Pharmacol Exp Ther       Date:  1994-06       Impact factor: 4.030

6.  Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies.

Authors:  F J Hock; K Wirth; U Albus; W Linz; H J Gerhards; G Wiemer; S Henke; G Breipohl; W König; J Knolle
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

7.  Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies.

Authors:  K Wirth; F J Hock; U Albus; W Linz; H G Alpermann; H Anagnostopoulos; S Henk; G Breipohl; W König; J Knolle
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

Review 8.  Bradykinin receptor types and B2 subtypes.

Authors:  D Regoli; F Gobeil; Q T Nguyen; D Jukic; P R Seoane; J M Salvino; D G Sawutz
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

9.  Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor.

Authors:  J F Hess; J A Borkowski; G S Young; C D Strader; R W Ransom
Journal:  Biochem Biophys Res Commun       Date:  1992-04-15       Impact factor: 3.575

10.  Expression cloning of a human B1 bradykinin receptor.

Authors:  J G Menke; J A Borkowski; K K Bierilo; T MacNeil; A W Derrick; K A Schneck; R W Ransom; C D Strader; D L Linemeyer; J F Hess
Journal:  J Biol Chem       Date:  1994-08-26       Impact factor: 5.157

View more
  11 in total

Review 1.  DNA antisense strategies in the study of receptors for vasoactive peptides, and of growth and wound-healing factors.

Authors:  P D'Orléans-Juste; M G Sirois; E R Edelman; D Regoli; L H Pheng; G Bkaily; C J Lindsey
Journal:  Mol Cell Biochem       Date:  1997-07       Impact factor: 3.396

Review 2.  Kinin receptors.

Authors:  F Marceau; D R Bachvarov
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

3.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

4.  Functional evidence of des-Arg10-kallidin enzymatic inactivating pathway in isolated human umbilical vein.

Authors:  Wanda Nowak; Ezequiel Dario Goldschmidt; Alejandra Georgina Falcioni; Mariana Ines Pugliese; Andrea Emilse Errasti; Facundo German Pelorosso; Federico Manuel Daray; Juan Ezequiel Gago; Rodolfo Pedro Rothlin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-20       Impact factor: 3.000

5.  Dual kinin B1 and B2 receptor activation provides enhanced blood-brain barrier permeability and anticancer drug delivery into brain tumors.

Authors:  Jérôme Côté; Martin Savard; Witold Neugebauer; David Fortin; Martin Lepage; Fernand Gobeil
Journal:  Cancer Biol Ther       Date:  2013-06-14       Impact factor: 4.742

6.  Characterization of dual agonists for kinin B1 and B2 receptors and their biased activation of B2 receptors.

Authors:  Xianming Zhang; Jessica L Lowry; Viktor Brovkovych; Randal A Skidgel
Journal:  Cell Signal       Date:  2012-04-12       Impact factor: 4.315

7.  Exacerbation of DSS-induced colitis in mice lacking kinin B(1) receptors through compensatory up-regulation of kinin B(2) receptors: the role of tight junctions and intestinal homeostasis.

Authors:  R Marcon; R F Claudino; R C Dutra; A F Bento; E C Schmidt; Z L Bouzon; R Sordi; R L T Morais; J B Pesquero; J B Calixto
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

8.  Pharmacological evidence of bradykinin regeneration from extended sequences that behave as peptidase-activated B2 receptor agonists.

Authors:  Xavier Charest-Morin; Caroline Roy; Emile-Jacques Fortin; Johanne Bouthillier; François Marceau
Journal:  Front Pharmacol       Date:  2014-03-07       Impact factor: 5.810

9.  Species-specific pharmacology of maximakinin, an amphibian homologue of bradykinin: putative prodrug activity at the human B2 receptor and peptidase resistance in rats.

Authors:  Xavier Charest-Morin; Hélène Bachelard; Melissa Jean; Francois Marceau
Journal:  PeerJ       Date:  2017-01-18       Impact factor: 2.984

10.  D-Arg0-Bradykinin-Arg-Arg, a Latent Vasoactive Bradykinin B2 Receptor Agonist Metabolically Activated by Carboxypeptidases.

Authors:  Hélène Bachelard; Xavier Charest-Morin; François Marceau
Journal:  Front Pharmacol       Date:  2018-03-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.